Atlas Trials

Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere

Clinical trial NCT06900543 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06900543
Sponsor
Chengdu New Radiomedicine Technology Co. LTD.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Unresectable Hepatocellular Carcinoma
Start date
2025-04-15
Primary completion
2027-10-01
Enrollment
108

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.